Clinical trials: Diabetes Mellitus, Type 1, Type 2
Insulin Hypoglycemia, Type 1 Diabetes Mellitus
G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way crossover efficacy and safety study in subjects with Type 1 diabetes mellitus.
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Trial name
- NCT03439072
- Testing
- G-Pen, Lilly Glucagon
- Where
- 6 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Type 2
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.
- Trial name
- NCT00461136
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- Novartis
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.
- Trial name
- NCT01076634
- Testing
- insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT05887999
- Testing
- LY3532226
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type1 Diabetes Mellitus
Comparison Between Enlite and Flash Glucose Monitoring
1. The accuracy of the sensors (Flash vs Enlite glucose monitoring) will be evaluated with a standardized breakfast test. Patients receive a standardized breakfast. The usual insulin bolus will be administered at breakfast.
- Trial name
- NCT03249974
- Testing
- Enlite sensor communicating with Minimed 640G pump
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jessa Hospital
Type 1 Diabetes
Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin
The goal of this clinical trial is to compare glycemic control and variability between children and adolescents with type 1 diabetes treated by a two daily injection of premixed human insulin (Humulin 30/70) and those who have a…
- Trial name
- NCT05768191
- Testing
- premix insulin human isophane suspension and insulin human, Humulin N plus Humulin R
- Where
- 3 sites in Burkina Faso
- Volunteers
- 22 people
- Sponsor
- Université NAZI BONI
Diabetes Mellitus, Diabetes Mellitus, Type 2
Emotional Wellbeing in Diabetes
The investigators want to understand the feasibility and acceptability of implementing COMPASS: Online Cognitive behavioural therapy (CBT) in routine NHS care for individuals with diabetes.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes
- Trial name
- NCT05140551
- Testing
- COMPASS: digital CBT
- Where
- 4 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- King's College London
Type One Diabetes Mellitus
Islet Function and Clinical Analyses of Transplant Recipients
To follow the patterns and natural history of Islet Transplant recipients (the ones that were involved in the Modified Edmonton Protocol) using oral glucose to check sugar levels as well as insulin and C-peptide over the course…
- Trial name
- Islet OGTT (NCT00870831)
- Testing
- OGTT (Oral Glucose Tolerance Test)
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 2
Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)
This study is to characterize the pharmacokinetics, safety, tolerability, and pharmacodynamics of single and multiple oral doses (SD, MD) of ertugliflozin (PF-04971729, MK-8835) in Japanese healthy participants.
- Trial name
- NCT01223339
- Testing
- Ertugliflozin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Type 2 Diabetes
Breaking Down Barriers to Diabetes Self-Care
Performance of self-care recommendations is key to the successful treatment of diabetes. However, many patients have difficulty adhering to diabetes self-care recommendations.
- Trial name
- NCT00142922
- Testing
- Breaking Down Barriers
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Diabetes Mellitus, Type 1
NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
This study is conducted in Asia. The aim of this study is to investigate the safety and efficacy of NovoLet® human insulin delivery system in an outpatient setting.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01492153
- Testing
- biphasic human insulin, isophane human insulin, human soluble insulin
- Where
- Indonesia
- Volunteers
- 1,981 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Microvascular Dysfunction
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes
- Trial name
- EGOFIP (NCT01931982)
- Testing
- Victoza
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Bispebjerg Hospital
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00134147
- Testing
- Inhaled Insulin
- Where
- 121 sites in United States, Canada and 5 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Gastroparesis
Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
- Trial name
- NCT00370084
- Testing
- Itopride
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes Mellitus, Cognitive Impairment
Intensive Aerobic and Resistance Exercise Program (IAREP)
A 12-week Intensive Aerobic and Resistance Exercise Program (IAREP) intervention was implemented on high-risk and low-risk subjects with cognitive impairment in type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes Mellitus, Cognitive Impairment, Non-insulin-dependent Diabetes Mellitus, Cognitive Dysfunction
- Trial name
- NCT06401733
- Testing
- Intensive Aerobic and Resistance Exercise Program (IAREP)
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University of Singapore
Dyslipidemias, Diabetes Mellitus, Type 2
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes.
- Trial name
- NCT01217112
- Testing
- GWP42003, GWP42004
- Where
- 5 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- Jazz Pharmaceuticals
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Retinal Function in Diabetic Patients Without Retinopathy
The primary purpose was to assess, in diabetic patients without diabetic retinopathy and control subjects, color vision, contrast sensitivity, electroretinography, and flicker-induced vasodilatation using the Dynamic Vessel…
- Trial name
- NEURODIAB (NCT00839150)
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-insulin-dependent Diabetes
Statin Compliance of Patients With Non-insulin-dependent Diabetes
The diabetic population has an increased cardiovascular risk compared to the general population. Hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase) inhibitors, or "statins", are considered as the standard treatment for…
- Trial name
- DIOS (NCT04007133)
- Testing
- Girerd test
- Where
- France
- Volunteers
- 119 people
- Sponsor
- Lille Catholic University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.